On May 6, 2026, CMS confirmed that its Medicare GLP-1 Bridge demonstration will launch July 1. Medicare Part D beneficiaries who meet clinical criteria can access brand-name GLP-1 weight loss medications — Wegovy (pill and injection), Zepbound KwikPen, and Foundayo — for a flat $50 monthly copay.
That's the headline. Here's what they're not highlighting.
The $50 Doesn't Count Toward Anything
This is the biggest gotcha. The $50 copay operates outside the normal Part D benefit structure:
- It does not count toward your Part D annual deductible
- It does not count toward the $2,100 annual out-of-pocket maximum
- If you receive the Low-Income Subsidy (Extra Help), you cannot apply that assistance to Bridge drugs
In plain English: this $50 is a completely separate expense that doesn't reduce any of your other Medicare drug costs.
Only Brand-Name, FDA-Approved Products
The Bridge covers three specific products: Wegovy (semaglutide — injection and daily pill), Zepbound KwikPen (tirzepatide injection), and Foundayo (orforglipron daily pill, pending FDA approval expected June 2026). Compounded GLP-1 medications are explicitly excluded. So are Ozempic and Mounjaro, which are approved for diabetes only — not weight loss.
The $50 vs. Your Current Cost
If you're self-paying $349/mo for Wegovy or $199–299/mo for compounded semaglutide through telehealth, $50 is obviously better for brand-name access. But if you're on a compounded product at $99–149/mo and satisfied with it, switching to the Bridge means changing your medication source for a modest savings — and your compounded option won't be available through Medicare.
Eligibility Requirements
You need all three: Medicare Part D enrollment, BMI ≥30 (or ≥27 with a weight-related comorbidity), and a prescriber who submits a prior authorization confirming you meet criteria. If you're already on a GLP-1 and your BMI has dropped below threshold due to treatment success, your prescriber can attest to your starting BMI.
The 18-Month Clock
The Bridge runs July 2026 through December 2027. After that, the full BALANCE Model is supposed to take over in Medicare Part D starting January 2027. But "supposed to" and "will" are different words in government programs. If you start on the Bridge, plan for the possibility of a coverage gap.
Research consistently shows most patients regain weight when they stop GLP-1 medications. Starting a medication through a program that explicitly expires creates a risk worth discussing with your doctor upfront.
Sesame Care
Access FDA-approved Wegovy and Zepbound through licensed providers. Same-day appointments, all 50 states. No compounded medications.
Check Eligibility →Our Take
The Bridge is a genuinely good development for Medicare beneficiaries who want brand-name GLP-1 access. $50/month for Wegovy or Zepbound is substantially below any other available price. But go in with eyes open: this is a temporary demonstration, the copay structure is disadvantageous compared to normal Part D benefits, and you're limited to specific brand-name products.
For beneficiaries who are comfortable with compounded GLP-1 medications and currently paying $99–199/month through telehealth, the Bridge may not actually save you money once you factor in the brand-only restriction and the transition cost of switching medications.
Embody
For patients who don't qualify for Medicare Bridge or prefer compounded options. Embody offers injectable semaglutide with custom metabolic reports and HSA/FSA acceptance.
Compare Now →